# A Review of Therapeutic Antibodies in Breast Cancer

CorpusID: 236451912 - [https://www.semanticscholar.org/paper/ec6f8dadcb270d0f13c88d260115bab847d37626](https://www.semanticscholar.org/paper/ec6f8dadcb270d0f13c88d260115bab847d37626)

Fields: Medicine

## (s9) Toxicity:
(p9.0) Hepatitis, water-electrolyte imbalance, and rash (without any grade 4 or 5 side effects) were the most common related adverse events of durvalumab in TNBC or metastatic endocrine receptor (ER) positive patients (95).
